Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Europe to Invest €3.8 Billion in the Biobased Economy

Published: Monday, July 15, 2013
Last Updated: Monday, July 15, 2013
Bookmark and Share
48 Companies join forces with the European Commission to set up a Public-Private Partnership and accelerate the deployment of biobased products in Europe.

The European Commission proposed a €3.8 billion Public Private Partnership (PPP) on Biobased Industries, in order to accelerate the commercialization of biobased products in Europe. The European Commission will invest €1 billion and industry €2.8 billion, from 2014 to 2020, to boost market uptake of new biobased products that are “made in Europe”.

The partnership promotes the use of various sources of sustainable biomass and waste to produce everyday products such as food, feed, chemicals and fuels. The use of local biomass and waste will generate growth and jobs in rural areas across European regions, while reducing the EU’s reliance on fossil fuels, thereby offering sustainable alternatives to oil-based products and enhancing energy and food security.

Novozymes is part of this initiative alongside 47 leading European companies in the biotech, chemical, energy, agro-food and pulp and paper sectors.

“The Biobased Industries PPP is essential for Europe to remain competitive in the global race for the development of a biobased economy,” says Novozymes CEO Peder Holk Nielsen. “It is an opportunity for reindustrialization and for reversing the investment trend currently going to other regions of the world because of more attractive policy frameworks.”

The PPP will capitalize on Europe’s innovation and technological leadership to bring biobased solutions from research labs to the market. Various sectors will be brought together to optimize and create new value chains, such as connecting farmers and foresters directly to consumers.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Adisseo,Novozymes Enter Partnership in Probiotics for Animals
The companies will develop a product based on naturally occurring microbes that can reduce antibiotic usage in poultry and brings associated health benefits.
Monday, June 01, 2015
Novozymes, Cargill Continue Bio-Acrylic Acid Partnership as BASF Exits
Novozymes and Cargill remain committed to bringing technology to market.
Wednesday, January 28, 2015
Novozymes, Monsanto Showcase Innovations Expected to Increase Farm Sustainability
Companies’ BioAg Alliance working to develop innovations for agriculture to boost productivity.
Thursday, August 28, 2014
Novozymes and Monsanto Partner
Companies establish The BioAg Alliance to discover, develop and sell microbial solutions which enable farmers to increase crop yields with less input.
Tuesday, December 17, 2013
Novozymes and Raízen to Collaborate on Cellulosic Ethanol
Novozymes will supply enzyme technology to Raízen’s first commercial-scale cellulosic ethanol plant in Brazil.
Friday, September 20, 2013
Novozymes Biopharma Helps Innovative Dry Eye Therapy Move into Clinical Trials
A novel ophthalmic solution has recently obtained FDA approval to undergo Phase I/II clinical trials in the United States.
Monday, May 20, 2013
Novozymes' New CEO Takes Office
Peder Holk Nielsen takes over from Steen Riisgaard in a planned transition, vows to bring more innovation to the market faster.
Tuesday, April 02, 2013
Novozymes Acquires Enzyme Business from Iogen Corporation
The acquisition complements Novozymes’ existing business in the pulp & paper, textile, grain-processing and animal feed industries.
Monday, February 04, 2013
Novozymes and Syngenta Enter Global Commercial Agreement
The partners are entering into an exclusive global marketing and distribution agreement on a unique biofungicide used to combat damaging fungal diseases across a range of crops.
Friday, October 26, 2012
Novozymes and Syngenta to partner in delivering JumpStart® — For enhanced phosphate fertility within bioagriculture
The agreement provides an exclusive expansion into new markets for JumpStart, which is a biological that enhances phosphate fertility in agriculture, offering growers an integrated and sustainable seed care solution
Friday, May 11, 2012
Shengquan and Novozymes in partnership to commercialize cellulosic ethanol
The Chinese Shengquan Group will start commercial production of cellulosic ethanol for solvents and biochemicals in June 2012 utilizing enabling technology from Novozymes
Friday, May 11, 2012
Novozymes reaches 2011 financial targets; cautious 2012 outlook
Novozymes, the world leader in bioinnovation and industrial enzymes, today reported satisfactory 2011 results in line with expectations.
Tuesday, January 24, 2012
Novozymes Biopharma to Present Latest Research on Recombinant Human Albumin at AAPS
Recombinant human albumin as a multifunctional excipient for the stabilisation of therapeutic protein formulations. Study results to be presented at the 2011 AAPS National Biotechnology Conference.
Wednesday, March 23, 2011
Novozymes Announces Master File for Recombinant Albumin
The dossier, containing information on the manufacture and safety of albucult, can help support the medical devices and drug formulation applications.
Friday, September 03, 2010
Novozymes Showcases Biopharmaceutical Solutions at BioProcess International 2010
The Company plans to feature its range of regulatory compliant, recombinant and animal-free products and technologies at the annual conference.
Friday, September 03, 2010
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Lab-on-a-Chip Offers Promise for TB and Asthma Patients
A device to mix liquids using ultrasonics is the first and most difficult component in a miniaturized system for low-cost analysis of sputum from patients with pulmonary diseases such as tuberculosis and asthma.
Intracellular Microlasers Could Allow Precise Labeling of up to a Trillion Individual Cells
MGH investigators have induced structures incorporated within individual cells to produce laser light at wavelengths that differ based on the size, shape and composition of each microlaser, allowing precise labeling of individual cells.
Real-Time Imaging of Lung Lesions During Surgery
Targeted molecular agents cause lung adenocarcinomas to fluoresce during surgery, according to pilot report.
Watching a Tumour Grow in Real-Time
Researchers from the University of Freiburg have gained new insight into the phases of breast cancer growth.
Protein Related to Long Term Traumatic Brain Injury Complications Discovered
NIH-study shows protein found at higher levels in military members who have suffered multiple TBIs.
Childhood Cancer Cells Drain Immune System’s Batteries
Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for the body’s immune cells, leaving them too physically drained to fight the disease.
Urine Proteins Point to Early-Stage Pancreatic Cancer
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers at the BCI have shown.
Researcher Discovers Trigger of Deadly Melanoma
New research sheds light on the precise trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, pinpointing the precise place in the process where "traveling" cancer turns lethal.
New Vaccine For Chlamydia to Use Synthetic Biology
Prokarium Ltd, a biotechnology company developing transformational oral vaccines, have announced new funding from SynbiCITE, the UK’s Innovation and Knowledge Centre for Synthetic Biology.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!